Prognosis of nonmetastatic rhabdomyosarcoma according to site of primary tumor from two different clinical trials

Site of primary tumor	Five year rates, percent
	MMT-89		IRS-IV
	OS	EFS	OS	EFS
Orbit	85	53	100	93
Genitourinary (not bladder or prostate)	94	82	90	83
Genitourinary (bladder or prostate)	80	64	86	79
Head and neck (nonparameningeal)	64	35	89	83
Head and neck (parameningeal) <3 years of age	59	33	64	60
Head and neck (parameningeal) ≥3 years of age	65	62	78	73
Limbs	46	35	71	64
Other	63	54	81	77

MMT-89: International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study-89; IRS-IV: Intergroup Rhabdomyosarcoma Study Group IV protocol; OS: overall survival; EFS: event-free survival.

Data from: Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol 2005; 23:2586.

Graphic 76178 Version 5.0

خرید پکیج

Prognosis of nonmetastatic rhabdomyosarcoma according to site of primary tumor from two different clinical trials